SecBot SecBot

ACRS

Aclaris Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001557746 Biotech & Drug Discovery
$3.75 −0.08 (−2.09%)
Oct 23 4:00 PM ET · prev $3.83
Market cap
$563.8M
Small cap
Consensus
Buy
89% Buy or better · 19 analysts
Median target
🔒 Subscribers only
1 year
+74.4%
from $2.15 · Oct 24
30 days
−30.3%
from $5.38
52-week range
$2.13–6.53
−43% from high · low Nov 10
Avg volume 20D
3.95M
shares / day
Short interest
18.19M
≈12.4% of shares · +13.2%
Days to cover
6.5
at average volume
Insider net
-$1.4M
0 buyers · 1 seller · since Feb 1
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH A strong institutional accumulation cluster in Aclaris Therapeutics during Q2 2026, with 10 buyers adding…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.4M.

  • InstitutionsBULLISH

    Q2 2026: 37 added (0 new), 9 trimmed or exited.

  • AnalystsBULLISH

    17 of 19 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +13.2% to 18.19M shares. 6.5 days to cover, ≈12.4% of shares.

  • TrendDOWNTREND

    27% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RA CAPITAL MANAGEMENT, L.P.ADD12,723,026$67.3M
BlackRock, Inc.ADD10,037,008$53.1M
STATE STREET CORPADD3,255,340$17.2M
GEODE CAPITAL MANAGEMENT, LLCADD3,190,058$16.9M
BALYASNY ASSET MANAGEMENT L.P.TRIM2,023,470$10.7M
PANAGORA ASSET MANAGEMENT INCDOUBLED1,356,152$7.2M
NORTHERN TRUST CORPADD998,763$5.3M
VANGUARD FIDUCIARY TRUST COADD907,173$4.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 89% rate it Buy or better
Strong Buy8Buy9Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 1, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Jun 2, 2026LifeSci Capital
INITIATE
INITIATEOutperform
May 5, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
May 5, 2026Guggenheim
INITIATE
INITIATEBuy
Apr 29, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$1.4M
sold · 1 insider
DateInsiderTypeValue
Aug 1, 2026
Kolbeck Roland Wilhelm
Chief Scientific Officer
EXERCISE36,375 sh
Aug 1, 2026
Kolbeck Roland Wilhelm
Chief Scientific Officer
TAX W/H$64.4K
Jun 5, 2026
MILANO VINCENT
Director
EXERCISE11,580 sh
Jun 5, 2026
GOWEN MAXINE
Director
EXERCISE11,580 sh
Jun 5, 2026
Molineaux Christopher P.
Director
EXERCISE11,580 sh
Jun 5, 2026
Mehra Anand
Director
EXERCISE11,580 sh
Jun 5, 2026
SCHIFF ANDREW N
Director
EXERCISE11,580 sh
Jun 5, 2026
Humphries William D.
Director
EXERCISE11,580 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
18,191,280
shares short
+13.2%
vs prior settlement
6.5
days to cover
≈12.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 3, 2026 Other
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Aug 11, 2026 SEC
A strong institutional accumulation cluster in Aclaris Therapeutics during Q2 2026, with 10 buyers adding $43.5M in…
INST-CLUSTER — Impact 5/10
Aug 6, 2026 SEC
Aclaris Therapeutics reported Q2 2026 net loss of $21.5M ($-0.15/share) on revenue of $1.6M, slightly better than…
8-K — Impact 4/10
Aug 1, 2026 Insider
Kolbeck Roland Wilhelm acquired via exercise 36,375 shares
Chief Scientific Officer
Aug 1, 2026 Insider
Kolbeck Roland Wilhelm surrendered for taxes 12,385 shares
Chief Scientific Officer @ $5.20 ($64.4K)
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — ADD
12,723,026 shares ($67.3M)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
10,037,008 shares ($53.1M)
Jun 5, 2026 Insider
MILANO VINCENT acquired via exercise 11,580 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 29, 2026
Clinical Trial
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Sep 28, 2026
Clinical Trial
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
Phase Phase 2 — COMPLETED
Sep 3, 2026
Press release
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Aug 12, 2026
Earnings date
ACRS Q2 2026 Earnings Scheduled — 2026-08-12
Aug 6, 2026
Press release
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

SecBot reports

7 filings · 4 press releases · 3 bullish · 0 bearish · 1 mixed · 3 neutral
All ACRS filing & press-release reports (11)